Pliant Therapeutics announced two presentations on its drug PLN-101095 at the 2026 Society for Immunotherapy of Cancer meeting. The presentations will cover how targeting integrins αvβ8 and αvβ1 enhances immune checkpoint inhibitor therapy and plasma biomarkers predicting response to treatment. PLN-101095 is in a Phase 1a/1b trial for advanced solid tumors resistant to immune checkpoint inhibitors, including lung and kidney cancers. This highlights Pliant's progress in developing integrin-based cancer therapies and ongoing clinical evaluation.
Pliant Therapeutics' recent presentations at the 2026 Society for Immunotherapy of Cancer meeting provide context for readers. For those following the health sector, 106 of 150 US health stocks on Pluang rose today. Notable movers include TDOC at USD 8.74 with a 27.03% increase and ALNY at USD 177.80 down 23.49%, as of Oct 30, 2026 03:11 WIB.
iHerb Holdings appointed Jordan Sweetnam, eBay's Chief Commercial Officer, as an independent director to its board. Sweetnam brings extensive experience in global eCommerce, having held senior roles at eBay and Walmart, and will support iHerb's expan...
SAP, a global enterprise software leader, will merge its North Texas operations into a new office in Addison, Texas, relocating about 1,000 employees from Plano and Allen. The new Spectrum Center location will house business operations, software deve...
Ipsos has appointed Mitch Barns as Chairman and CEO for the Americas region, effective November 2, 2026. Barns brings extensive leadership experience from his previous roles as Global CEO of Nielsen and CEO of The Opus Group, positioning him to drive...
Republic Services posted Q3 net income of $592 million, or $1.93 per share, up from $550 million a year earlier, driven by strong revenue growth and operational resilience. The company raised its full-year 2026 revenue and adjusted EBITDA guidance, r...
Miami International Holdings (MIAX) posted strong Q3 2026 results with net revenue up 20% to $131 million and adjusted EBITDA rising 47% to $70.8 million, driven by growth in its options business and increased market share. Adjusted diluted EPS impro...
